Real-World Insights Into Chronic Lymphocytic Leukemia Prevalence and Bruton Tyrosine Kinase Inhibitor Treatment Landscape Analysis
Author(s)
Vassiki Sanogo, BA, MSc, PhD1, Karam Diaby, BSc, MSc, PhD2.
1HEOR | Data Scientist, Integrity Analytics, Lakeland, FL, USA, 2Otsuka, Princeton, NJ, USA.
1HEOR | Data Scientist, Integrity Analytics, Lakeland, FL, USA, 2Otsuka, Princeton, NJ, USA.
OBJECTIVES: Chronic lymphocytic leukemia (CLL) is a prevalent hematological malignancy, with treatment strategies evolving, particularly with the introduction of Bruton tyrosine kinase inhibitors (BTKis) like Ibrutinib, Acalabrutinib, and Zanubrutinib. This study aimed to analyze treatment patterns and outcomes in CLL patients, as well as CLL prevalence.
METHODS: A retrospective descriptive analysis was conducted using a dataset of 350 CLL patients from Integra Connect over 2008 to 2021. Data analytics were performed using descriptive statistics to estimate CLL diagnosed patients, treatment market shares, and therapy duration of BTKis. Summary statistics were estimated. The Wilcoxon rank sum test and Fisher's Exact Test were used to compare Ibrutinib and Acalabrutinib patient groups.
RESULTS: Of the 350 CLL patients 74% were 1L BTKis, 49% female and 51% male, and were inducted (28.6%). The average age was 66 years and 4 refills per patient. The descriptive analysis for first-line BTKis revealed a significant rise (34.6%) in CLL diagnoses from 2008 to 2020, followed by a decline (19.4%) in 2021. BTKis’ market share analysis from 2018 to 2021 showed Ibrutinib's share declined (Male: 100% to 22%; Female: 75% to 25%), Acalabrutinib's increased (Male: 0% to 78%; Female: 25% to 75%), and Zanubrutinib was female-specific (2% in 2020). Median duration of therapy was longer for Acalabrutinib (424 days, IQR = 421.5) than Ibrutinib (369 days, IQR = 578.0) with no statistically significant differences.
CONCLUSIONS: This analysis highlights evolving trends in CLL treatment shows a shift from Ibrutinib to Acalabrutinib, with gender-specific Zanubrutinib uptake. Diagnoses peaked in 2020 before declining. Longer therapy duration for Acalabrutinib suggests efficacy benefits. Clinically, optimizing BTKi selection based on demographics and efficacy remains key. Policy efforts should ensure equitable access to evolving treatments and real-world data integration to refine CLL management and improve patient outcomes.
METHODS: A retrospective descriptive analysis was conducted using a dataset of 350 CLL patients from Integra Connect over 2008 to 2021. Data analytics were performed using descriptive statistics to estimate CLL diagnosed patients, treatment market shares, and therapy duration of BTKis. Summary statistics were estimated. The Wilcoxon rank sum test and Fisher's Exact Test were used to compare Ibrutinib and Acalabrutinib patient groups.
RESULTS: Of the 350 CLL patients 74% were 1L BTKis, 49% female and 51% male, and were inducted (28.6%). The average age was 66 years and 4 refills per patient. The descriptive analysis for first-line BTKis revealed a significant rise (34.6%) in CLL diagnoses from 2008 to 2020, followed by a decline (19.4%) in 2021. BTKis’ market share analysis from 2018 to 2021 showed Ibrutinib's share declined (Male: 100% to 22%; Female: 75% to 25%), Acalabrutinib's increased (Male: 0% to 78%; Female: 25% to 75%), and Zanubrutinib was female-specific (2% in 2020). Median duration of therapy was longer for Acalabrutinib (424 days, IQR = 421.5) than Ibrutinib (369 days, IQR = 578.0) with no statistically significant differences.
CONCLUSIONS: This analysis highlights evolving trends in CLL treatment shows a shift from Ibrutinib to Acalabrutinib, with gender-specific Zanubrutinib uptake. Diagnoses peaked in 2020 before declining. Longer therapy duration for Acalabrutinib suggests efficacy benefits. Clinically, optimizing BTKi selection based on demographics and efficacy remains key. Policy efforts should ensure equitable access to evolving treatments and real-world data integration to refine CLL management and improve patient outcomes.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD160
Topic
Real World Data & Information Systems
Topic Subcategory
Reproducibility & Replicability
Disease
Oncology